Results 171 to 180 of about 24,248 (200)
Some of the next articles are maybe not open access.
Chemotherapy of Human African Trypanosomiasis
Current Pharmaceutical Design, 2002Human African trypanosomiasis or sleeping sickness is resurgent [1,2]. The disease is caused by subspecies of the parasitic haemoflagellate, Trypanosoma brucei. Infection starts with the bite of an infected tsetse fly (Glossina spp.). Parasites move from the site of infection to the draining lymphatic vessels and blood stream. The parasites proliferate
Richard J S, Burchmore +3 more
openaire +2 more sources
Drug Resistance in Human African Trypanosomiasis
Future Microbiology, 2011Human African trypanosomiasis or 'sleeping sickness' is a neglected tropical disease caused by the parasite Trypanosoma brucei. A decade of intense international cooperation has brought the incidence to fewer than 10,000 reported cases per annum with anti-trypanosomal drugs, particularly against stage 2 disease where the CNS is involved, being central ...
Michael P, Barrett +4 more
openaire +2 more sources
Recent developments in human African trypanosomiasis
Current Opinion in Infectious Diseases, 2002Sleeping sickness has re-emerged as a serious problem in sub-Saharan Africa, with an estimated 100000 deaths each year. South Sudan, the Democratic Republic of Congo and Angola have experienced serious epidemics of the Gambian form of the disease.
Susan C, Welburn, Martin, Odiit
openaire +2 more sources
Human African trypanosomiasis–neurological aspects
Journal of Neurology, 2006Human African Trypanosomiasis (HAT),which is also known as sleeping sickness, is a major cause of death and disability in 36 countries in sub-Saharan Africa. The disease is caused by the protozoan parasite of the Trypanosoma genus which is transmitted by the bite of the tsetse fly.
openaire +2 more sources
Treatment perspectives for human African trypanosomiasis
Fundamental & Clinical Pharmacology, 2003AbstractHuman African trypanosomiasis (HAT), or sleeping sickness, is currently on the rise. HAT develops in two stages, the first involving the hemolymphatic system, and the second, the neurological system. Left untreated, HAT is invariably fatal. There have been no therapeutic advances in more than 40 years.
Bernard, Bouteille +3 more
openaire +2 more sources
New developments in human African trypanosomiasis
Current Opinion in Infectious Diseases, 2006To review recent literature on human African trypanosomiasis, focussing on genome sequencing, diagnosis and drug discovery, and typing of trypanosomes.The most important recent development has been the completion of the Trypanosoma brucei genome which will greatly facilitate the discovery of new drug targets and genetic markers.
Brun, Reto, Balmer, Oliver
openaire +3 more sources
Current chemotherapy of human African trypanosomiasis
Parasitology Research, 2003Human African trypanosomiasis is a fatal disease caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense that has re-emerged in recent years. However, very little progress has been made in the development of new drugs against this disease.
Roberto, Docampo, Silvia N J, Moreno
openaire +2 more sources
Human African Trypanosomiasis (HAT)
2016Human African trypanosomiasis (HAT) found only in sub-Saharan Africa is caused by the parasite Trypanosoma brucei which is transmitted by tsetse flies. Only two subspecies of T.brucei are pathogenic for humans: T.b. gambiense and T.b. rhodesiense. HAT is endemic in 36 sub-Saharan countries, and 98 % of all reported HAT cases are due to T. b. gambiense.
Pascal Lutumba +2 more
openaire +1 more source
Cancer statistics for African American/Black People 2022
Ca-A Cancer Journal for Clinicians, 2022Angela Giaquinto +2 more
exaly